Merz Neuroscience, a division of Merz North America, today announced that Kevin O’Brien will join as the Vice President and U.S. Head of Neurosciences, effective immediately. Mr. O’Brien will relocate to the Merz North America headquarters in Raleigh, N.C.

“We are honored to have Kevin join Merz with his proven track record of success leading sales and marketing teams globally and his extensive industry knowledge. He is highly collaborative and will be a strong and strategic addition to our leadership team,” commented Bob Rhatigan, President and CEO of Merz North America. “We are deeply committed to the neurotoxins field and ultimately to helping patients who suffer from movement disorders.”

In his new role, Mr. O’Brien will assume responsibility for the U.S. neuroscience business including oversight of field sales, managed markets and marketing. He will also join the North America Leadership Team (NALT).

“I am honored and excited to lead the dynamic Merz U.S. neurosciences team in order to grow our position in the market and reach patients who are in need of innovative treatments,” said Mr. O’Brien. “Merz is globally recognized for its work in neurology. I plan to build upon the team’s legacy of innovation to help ensure that patients and their health care providers have access to Merz’s meaningful treatment options.”

Prior to joining Merz, Mr. O’Brien spent the last 16 years working for Allergan in the dermatology and aesthetics business. He is a global healthcare executive with over 25 years of experience in sales, leadership and business development in the United States, Canada and Asia Pacific. He has broad exposure in building and leading teams and product launches in medical aesthetics, plastic surgery, dermatology and injectables. Mr. O’Brien has held various positions at Allergan and outside of Allergan including J&J and Boston Scientific in both sales and marketing functions.

Merz North America is a significant contributor to the company’s global business in  both aesthetics and neurotoxins as the two areas of global strategic focus.

To learn more, visit

About Merz Neurosciences

Merz Neurosciences is a division of Merz North America and is deeply committed to offering novel therapeutic options that address the largely unmet medical needs that exist within the area of neuroscience. Merz Neurosciences is an important contributor to the U.S. neurosciences space and offers a portfolio that includes the neurotoxin Xeomin® (incobotulinumtoxinA), the anticholinergic Cuvposa® (glycopyrrolate) Oral Solution and the Prolaryn® injectable implant family of products. To learn more about Merz Neurosciences and their U.S. product portfolio, please visit

About Merz North America

Merz North America is a specialty healthcare company dedicated to the development and marketing of innovative quality products for physicians and patients across the United States and Canada. Merz products are distributed through two divisions, Aesthetics and Neurosciences, and are developed with the goal of improving patients’ health and quality of life by delivering therapies that bring about real progress. Merz North America is a privately-held company based in Raleigh, North Carolina. To learn more about Merz North America, please visit

Download File:
08.14.2017 [ 0 KB ]

Press Contact

Merz North America

Emily Browder
Corporate Communications


Phone: +1 919.582.8114

Merz in the Americas

Merz has a direct presence in six countries in the Americas, as well as a network of selected professional distribution partners in South and Central America and the Caribbean. Merz in the Americas is headquartered in Raleigh, North Carolina, and has facilities in Mesa, Arizona, Franksville, Wisconsin as well as offices in Toronto, Canada, Mexico City, Bogotá, Colombia, São Paolo, Brazil and Buenos Aires, Argentina.

Merz Worldwide

With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at

Media Contact – Global

Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466

Media Contact – North America

Merz North America, Inc.
Corporate Communications
Emily Browder
Phone: +1 919.582.8114